Skip to main content

Udenyca News

Coherus Announces FDA Approval of Udenyca Onbody™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

Innovative design enables five-minute pegfilgrastim delivery time Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving...

Updated FDA Labeling Recommendations for Biosimilar and Interchangeable Biosimilar Products

October 26, 2023 – Over the last eight years, FDA has approved more than 40 biosimilar products (biosimilars), and they have become an important treatment option for health care professionals and...

FDA Approves Fylnetra (pegfilgrastim-pbbk), a Biosimilar to Neulasta

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- May 27, 2022 – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has appr...

FDA Approves Udenyca (pegfilgrastim-cbqv), a Biosimilar to Neulasta

REDWOOD CITY, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration (FDA) has approved Udenyca...

FDA Approves Udenyca (pegfilgrastim-cbqv), a Biosimilar to Neulasta

REDWOOD CITY, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) – Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration (FDA) has approved Udenyca...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Neutropenia Associated with Chemotherapy

Udenyca patient information at Drugs.com